The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.

This Advisory, based on TIP 49, Incorporating Alcohol Pharmacotherapies Into Medical Practice, focuses on medication and related treatment decisions made after screening and assessment for AUD, and medically supervised withdrawal, if necessary. Alcohol consumption should not stop abruptly in those patients who have consumed alcohol regularly over a prolonged period of time. This Advisory is meant as an overview of AUD medications to facilitate abstinence.

This guide supports health care providers, systems, and communities seeking to prevent marijuana use by pregnant women. It describes relevant research findings, examines emerging and best practices, identifies knowledge gaps and implementation challenges, and offers useful resources.

This quick guide contains an overview of the challenges associated with tobacco cessation and the benefits of being tobacco-free for individuals as well as those of a smoke-free workplace. It also includes tips that substance use disorder treatment settings can use to implement their own tobacco cessation programs.

This pamphlet offers reasons to combine tobacco cessation and substance use disorder treatment, including client testimonials and resources for implementing a tobacco cessation program. It also explains the benefits of offering tobacco cessation programs in substance use disorder treatment settings.

This Clinical Guide provides comprehensive, national guidance for optimal management of pregnant and parenting women with opioid use disorder and their infants. The Clinical Guide helps healthcare professionals and patients determine the most clinically appropriate action for a particular situation and informs individualized treatment decisions.

This manual offers best practices to states, tribes, and local communities on collaborative treatment approaches for pregnant women living with opioid use disorders, and the risks and benefits associated with medication-assisted treatment.

This guide offers best practices for treating women living with substance use disorders in co-ed treatment and recovery settings. It highlights the importance of gender differences, cultural sensitivity, and developing healthy relationships.

This advisory summarizes data on the use of sublingual and transmucosal buprenorphine for the medication-assisted treatment of opioid use disorder.